Navigation Links
TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
Date:1/3/2012

p>TrovaGene has been building a franchise of proprietary markers in hematological oncology, including mutations in the nucleophosmin gene (NPM1), which are today widely used in the diagnosis of acute myeloid leukemia (AML), and the BRAF V600E mutation for diagnostic use in hairy cell leukemia (HCL).

"We believe that SF3B1 mutations have the potential to become key components of standard diagnostic panels with clinical utility in the management of patients suffering from CLL," states Antonius Schuh, TrovaGene's Chief Executive Officer. "We plan to offer laboratory-developed tests to detect SF3B1 mutations and to identify opportunities for the development of in-vitro diagnostic products incorporating our proprietary markers."

About TrovaGene, Inc.
Headquartered in San Diego, California, TrovaGene has focused on the development of its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

TrovaGene has a dominant patent position as relates to transrenal molecular testing. TrovaGene has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML). TrovaGene has filed a Form 10 with the SEC. More complete current information about TrovaGene is contained in the filing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TrovaGene's current expectations and a
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
3. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
4. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
5. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
6. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
7. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
8. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
9. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
10. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
11. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... NY (PRWEB) October 30, 2014 Whitehouse ... for its ICH Stability Testing and Package Test Capacity. ... investment centers on a dramatic increase in environmental chamber ... of stability, storage and aging samples to be securely ... of this major capital expenditure has already taken place ...
(Date:10/30/2014)... N.J. , Oct. 30, 2014  Regado Biosciences, ... it will hold a conference call and live audio ... EST to discuss its third quarter 2014 financial results. ... conference call by dialing (888) 347-1165 for domestic callers ... will be webcast live under the investor relations section ...
(Date:10/27/2014)... MILAN , October 27, 2014 ... the right to produce, exhibit and sell its ... sought to impeach their patent.      ... After four years of fighting, the definitive judgement ... designs and produces innovative and accessible hi-tech prostheses ...
(Date:10/27/2014)... Called the NOAH Protocol, this ... types of pediatric brain cancer. The implications for ... 30 years of research and development. Amber Larkin, ... one mom's determination can make a difference. ... and it’s only fitting that we’ve received FDA ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... Tengion, Inc. (Nasdaq: TNGN ), a leader in ... and live audio webcast on Friday, March 25, 2011 at ... its fourth quarter 2010 financial results.   To ... (international) and reference access code 55045101. This ...
... N.J., March 18, 2011 Today, the Access Group--a ... structure; the formation of 2 business entities, Promidian and ... senior executive team leaders. The Access ... health care and life sciences industries to provide full-service ...
... 17, 2011 Quest Diagnostics Incorporated (NYSE: ... announced that its ColoVantage test has been approved by ... of patients in the state. It is believed to ... a venal blood specimen to be approved by the ...
Cached Biology Technology:Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011 2Introducing the Access Group and Its New Business Entities 2Introducing the Access Group and Its New Business Entities 3Introducing the Access Group and Its New Business Entities 4Introducing the Access Group and Its New Business Entities 5Introducing the Access Group and Its New Business Entities 6New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 2New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 3
(Date:10/29/2014)... a ceremony held in New York City on September ... the American Cancer Society Professor of Genome Sciences and ... 2008 Honorary Doctor of Philosophy of Tel Aviv University, ... Medical Science. , In addition to her honorary degree ... at the TAU School of Medicine, and for the ...
(Date:10/29/2014)... those referred to as ,facultative, form part—together with other ... differentiates these cells from the others. However, they have ... to become stem cells again. This phenomenon is something ... cells that stimulate tissue growth, thus allowing the regeneration ... Knowledge of the underlying mechanism that allows these ...
(Date:10/29/2014)... in the living world compete with members of ... how much they invest into their competitive ability. ... get access to high-quality resources, while others seem ... the lower-quality resources that are left over for ... and human societies seems to fluctuate considerably over ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... other groups have created a map of the world,s ... temperatures, ultra-violet radiation, weather systems, sedimentation, as well as ... The study, say the authors, will help to ... by identifying reef systems where biodiversity is high and ...
... Viruses fill the ocean and have a significant effect ... professor of biology at UC Santa Barbara and his ... of Ecology, Evolution, and Marine Biology, is the senior ... week by the International Society for Microbial Ecology ...
... published online this week in Nature Genetics , ... with universities in China and Denmark reports the first ... type of bladder cancer. Recognizing the genetic ... healthy neighbors may allow early genetic screenings for cancer ...
Cached Biology News:Worldwide map identifies important coral reefs exposed to stress 2Worldwide map identifies important coral reefs exposed to stress 3Decade-long study reveals recurring patterns of viruses in the open ocean 2Decade-long study reveals recurring patterns of viruses in the open ocean 3University of Colorado Cancer Center genetically sequences most common bladder cancer 2
... The DNA Engine Dyad instrument is the ... Featuring MJ's world-class thermal performance, the ... display, as well as point-and-click navigation via ... Dyad can be easily and economically expanded ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
ID clarifier: platform...
... Tetrad 2 thermal cycler accommodates a ... heat-pump assemblies), which hold different types ... computer drives an advanced graphical interface ... lid temperatures. Peltier heat pumps, built ...
Biology Products: